+33 (0) 4 76 45 21 20 contact@sb-peptide.com
Select Page

C7

C7 – Cancer Peptides Selective peptide ligand for FRalpha, demonstrating specific binding to FRalpha expression cells and tumour targeting ability in vivo.   Technical specification Sequence : H-MHTAPGWGYRLS-OH MW : 1.374.7 g/mol Purity : > 95%...

FREG peptide

FREG peptide – Cancer Peptides PDGF-Ra agonist with in vitro and in vivo antimelanoma growth activity.   Technical specification Sequence : H-DPHIKLQLQAE-OH MW : 1.290.7 g/mol Purity : > 95% Counter-Ion : TFA Salts Delivery format : Lyophilized Price...

AD01 N-terminal Q

AD01 N-terminal Q – Cancer Peptides AD01 is a derivative of the FK506 binding protein-like (FKBPL), and exerts potent anti-angiogenic activity in vitro and in vivo to control tumour growth. Recent studies have shown that AD-01 inhibits Rac-1 activity, and...

Bevacizumab Light chain

Bevacizumab Light chain – Cancer Peptides Light chain of the bevacizumab monoclonal antibody, sold as the antitumour therapeutic Avastin. It prevents vascular endothelial growth factor (VEGF) from binding to VEGF receptors 1 and 2 thus inhibiting angiogenesis in...

ARF peptide

ARF peptide – Cancer Peptides ARF peptide, is the alternative frame (ARF) tumour suppressor protein which is expressed on the occurrence of oncogenic stimuli. It functions to prevent abnormal cell proliferation through inhibiting the p53 ubiquitin ligase protein...